Autor: Dr. med. Aristoteles Giagounidis, St.-Johannes-Hospital Duisburg, Duisburg-Hamborn
Quellenangabe: Deutsches MDS-Forum - Dresden 2006
Stand: 27.11.2006
Greenberg P, Cox C, LeBeau MM.
International scoring system for evaluating prognosis in myelodysplastic syndromes.
Blood 1997;89:2079-2088. PM:9058730
[Medline]
Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G.
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
Br J Haematol 2003;120:1037-1046. PM:12648074
[Medline]
Jadersten M, Montgomery SM, Dybedal I.
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.
Blood 2005;106:803-811. PM:15840690
[Medline]
Kuendgen A, Strupp C, Aivado M.
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
Blood 2004;104:1266-1269. PM:15155466
[Medline]
List A, Kurtin S, Roe DJ.
Efficacy of lenalidomide in myelodysplastic syndromes.
N Engl J Med 2005;352:549-557. PM:15703420
[Medline]
List AF, Dewald G, Bennet J.
Hematologic and cytogenetic (CTG) response to lenalidomide (CC5013) in patients with transfusion dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of a multicenter MDS-003 study.
J Clin Oncol 2005;23:2.
Molldrem JJ, Caples M, Mavroudis D.
Antithymocyte globulin for patients with myelodysplastic syndrome.
Br J Haematol 1997;99:699-705. PM:9401087
[Medline]
Raza A, List A, Bennett J.
Lenalidomide (CC5013)-induced red blood cell (RBC) transfusion-independence (TI) responses in low-/int-1 risk patients with myelodysplastic syndromes (MDS): results of the multicenter mds 002 study.
Leukemia research 2005;29:70.
Stadler M, Germing U, Kliche KO.
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.
Leukemia 2004;18:460-465. PM:14712285
[Medline]